Lacosamid Ratiopharm

Lacosamide, the active ingredient in Lacosamid Ratiopharm, is a sodium channel blocker presented as an oral tablet for oral use. It works by enhancing the slow inactivation of voltage‑gated sodium channels, stabilising hyper‑excitable neuronal membranes, and is prescribed as adjunctive therapy to reduce the frequency of partial‑onset (focal) seizures in patients with epilepsy.

GNH USA supplies Lacosamid Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable global distribution.

Lacosamide is indicated for focal seizure disorders and is used as part of an adjunctive treatment regimen in epilepsy. - Partial-onset (focal) seizures: reduces seizure frequency when added to existing antiepileptic therapy. - Refractory focal epilepsy: provides additional seizure control for patients not adequately managed by other medications. - Adjunctive therapy in epilepsy: used alongside other antiepileptic drugs to improve overall seizure management.

Lacosamide may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue - Diplopia - Somnolence

Serious or Rare Side Effects: - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction - Hypersensitivity reactions including anaphylaxis - Blood dyscrasias (e.g., agranulocytosis)

When prescribing Lacosamide, several safety considerations should be observed. - Renal impairment: assess renal function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction: obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: risk unknown; use only if potential benefit justifies potential risk. - Concomitant antiepileptic drugs: evaluate for possible efficacy or interaction issues. - Store at room temperature: keep in original packaging, protect from moisture and light.

Lacosamide can interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, markedly reducing lacosamide plasma levels. - Phenytoin: induces metabolism, leading to decreased lacosamide exposure. - Strong CYP2C19 inhibitors (e.g., fluconazole): increase lacosamide concentrations and risk of toxicity.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression and dizziness. - Other antiepileptics (valproate, levetiracetam): may require dose adjustments based on seizure control. - Hormonal contraceptives: lacosamide may reduce contraceptive effectiveness; consider alternative methods.